HFTP Investments, L.L.C. v. ARIAD Pharmaceuticals, Inc.

752 A.2d 115, 1999 WL 1261379
CourtCourt of Chancery of Delaware
DecidedDecember 9, 1999
DocketCivil Action 17501
StatusPublished
Cited by14 cases

This text of 752 A.2d 115 (HFTP Investments, L.L.C. v. ARIAD Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
HFTP Investments, L.L.C. v. ARIAD Pharmaceuticals, Inc., 752 A.2d 115, 1999 WL 1261379 (Del. Ct. App. 1999).

Opinion

OPINION

JACOBS, Vice Chancellor.

Pending is a motion to stay this action brought by HFTP Investments, L.L.C., (“HFTP”) for injunctive, declaratory, and damage relief, against the defendant, AR-LAD Pharmaceuticals, Inc. (“ARIAD”). HFTP claims that ARIAD has wrongfully refused to honor HFTP’s right both to convert and to have redeemed shares of ARIAD Series C Convertible Preferred Stock (the “Preferred Stock”) that HFTP acquired for $3,000,000 in 1998.

HFTP filed this action on October 26, 1999. Thirteen minutes later, ARIAD filed an action (the “New York action”) against HFTP and its investment advisor, Promethean Investment Group, L.L.C. (“Promethean”) in the United States District Court for the Southern District of New York (the “Southern District”). AR-IAD’s New York complaint asserts claims under both the Securities Exchange Act of 1934 (“Exchange Act”), and state common law, based upon the identical set of facts that will be presented to this Court. Stated differently, the defenses ARIAD will raise in this Delaware action are asserted as affirmative claims for relief in the New York action, specifically, claims for a declaratory judgment that ARIAD properly refused to convert (and, later, to redeem) HFTP’s Preferred Stock, because HFTP (and Promethean) had made misrepresentations to ARIAD and had also wrongfully manipulated the price of ARIAD’s stock.

Later that same day, HFTP moved for expedited proceedings in this case. The next day, ARIAD filed a motion to dismiss or stay this action in favor of its New York action. At an office conference held on October 29, 1999, this Court tentatively scheduled a trial date for January 18-21 and 24, 2000, subject to a ruling on AR-IAD’s motion to dismiss or stay. The parties subsequently briefed and argued that motion, 1 which will be denied for the reasons discussed below.

I. RELEVANT FACTS 2

ARIAD is a Delaware corporation with its principal place of business in Cambridge, Massachusetts. The company’s common shares are traded on the NASDAQ National Market. ARIAD develops novel and proprietary drug, products based on its knowledge of the inner workings of cells and the genes involved in disease.

HFTP is a New York limited liability company engaged principally in the business of investment and financial services. Promethean (which is not a party to this action) is a New York limited liability company also principally engaged in the business of investment and financial services. Promethean is an affiliate of HFTP, and is also its investment manager.

On November 8, 1998, HFTP and AR-IAD entered into a Securities Purchase Agreement (the “Agreement”) whereby HFTP acquired 3,000 shares of ARIAD Series C Preferred Stock for $3 million. The validity and enforceability of the Agreement is governed by New York law, but the terms under which the Preferred Stock may be converted into ARIAD’s common stock are set forth in ARIAD’s Certificate of Designations, which was filed with the Delaware Secretary of State. The Certificate of Designations provided holders of the Preferred Stock with the right to convert that stock into *117 ARIAD common stock from and after March 1999. The conversion rate would be determined by a formula, the denominator of which (in this case) is a “floating” Conversion Price. The effect of the floating Conversion Price is that if ARIAD’s common stock drops during the 22 trading day period immediately preceding the conversion, the Conversion Price would be lower and, accordingly, the number of common shares issued in the conversion would be higher. HFTP’s attempt to convert a portion of its Preferred Stock under this formula is what precipitated the dispute that eventuated in this litigation and the New York action.

At some point after HFTP acquired the Preferred Stock, HFTP (and Promethean) executed a series of short sales of ARIAD common stock. 3 ARIAD claims that HFTP (and Promethean) did this on a massive scale, 4 specifically to manipulate the price of its common shares downward in order to increase the number of shares HFTP could obtain on conversion. AR-IAD contends that this short selling campaign caused the price of its common stock to be severely depressed, and thereby enabled HFTP to convert its Preferred Stock for many more shares of ARIAD common than it would have received absent this scheme to artificially depress the value of the common. HFTP vigorously disputes this claim.

This state of affairs prompted ARIAD to demand that Promethean and HFTP cease their short selling activities, because they possessed material nonpublic information about ARIAD’s ongoing financing plans, which imposed upon HFTP and Promethean a duty not to trade ARIAD’s stock. 5 HFTP does not deny that it (and its affiliate, Promethean) engaged in short selling activity, but insists that that activity breached no contractual or other duty owed to ARIAD, and was lawful in all respects.

On October 12, 1999, ARIAD announced that it had entered into a letter of intent to sell ARIAD’s 50% interest in the Hoeehst-ARIAD Genomics Center for $40 million in cash, plus other valuable consideration. ARIAD contends that the announcement of this development generated a significant increase in ARIAD’s common stock price. The announcement also created significant financial exposure for Promethean, because of Promethean’s obligation to immediately cover 2.5 million ARIAD shares that it had sold short. For this reason, ARIAD contends, HFTP immediately submitted a conversion notice to ARIAD on October 13, 1999, seeking to convert 612 of its 3,000 shares of Series C Preferred Shares into 1,078,038 shares of ARIAD common stock. ARIAD refused to honor the conversion request, because the request was based on stock prices that had been artificially lowered by Promethean’s allegedly illegal short sales of ARIAD common stock while in possession of material inside information.

Thereafter, on October 14 and 20, 1999, representatives of ARIAD and Promethe *118 an attempted to negotiate a repurchase by ARIAD of HFTP’s Preferred Stock. During these negotiations both sides were preparing their complaints, which would be filed in their respective jurisdictions of choice. Both sides were clearly engaged in a race to the courthouse, as the complaints in both actions were filed on the same day — October 26, 1999. Although HFTP won that race (albeit only by 13 minutes), the reasons for its “victory” are hotly contested. ARIAD contends that during the negotiations HFTP fraudulently misled it into refraining from filing in order to pursue further negotiations; HFTP denies this and contends that if anyone was misled, it was HFTP. Because this dispute involves controverted facts, it cannot be resolved on the present record. The Court is therefore unable to find (as ARIAD claims it should) that ARIAD was misled — or worse, defrauded — into delaying the filing of its federal complaint.

This action and the New York action both rest upon the same facts.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sperling & Slater v. SilkRoad, Inc.
Superior Court of Delaware, 2022
Zilberstein v. Frankenstein
Superior Court of Delaware, 2021
GXP Capital v. Argonaut Manufacturing Services
Supreme Court of Delaware, 2021
AG Resource Holdings, LLC v. Thomas Bradford Terral
Court of Chancery of Delaware, 2021
Focus Financial Financial Partners, LLC v. Holsopple
Court of Chancery of Delaware, 2020
AlixPartners, LLP v. Giacomo Mori
Court of Chancery of Delaware, 2019
In re Bay Hills Emerging Partners I, L.P.
Court of Chancery of Delaware, 2018
Hamilton Partners, L.P. v. Englard
11 A.3d 1180 (Court of Chancery of Delaware, 2010)
In Re Citigroup Inc. Shareholder Derivative Litigation
964 A.2d 106 (Court of Chancery of Delaware, 2009)
Brandin v. Deason
941 A.2d 1020 (Court of Chancery of Delaware, 2007)
Jewish Home for Elderly of Fairfield County, Inc. v. Cantore
778 A.2d 93 (Supreme Court of Connecticut, 2001)
Friedman v. Alcatel Alsthom
752 A.2d 544 (Court of Chancery of Delaware, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
752 A.2d 115, 1999 WL 1261379, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hftp-investments-llc-v-ariad-pharmaceuticals-inc-delch-1999.